An MMP-2 Responsive Liposome Integrating Antifibrosis and Chemotherapeutic Drugs for Enhanced Drug Perfusion and Efficacy in Pancreatic Cancer
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Fibrotic stroma, a critical character of pancreatic tumor microenvironment, provides a critical barrier against the penetration and efficacy of various antitumor drugs. Therefore, new strategies are urgently needed to alleviate the fibrotic mass and increase the drug perfusion within pancreatic cancer tissue. In our current work, we developed a β-cyclodextrin (β-CD) modified matrix metalloproteinase-2 (MMP-2) responsive liposome, integrating antifibrosis and chemotherapeutic drugs for regulation of pancreatic stellate cells (PSCs), a key source of the fibrosis, and targeted delivery of cytotoxic drugs for pancreatic cancer therapy. These liposomes disassembed into two functional parts upon MMP-2 cleavage at the tumor site. One part was constituted by the β-CDs and the antifibrosis drug pirfenidone, which was kept in the stroma and inhibited the expression of collagen I and TGF-β in PSCs, down-regulating the fibrosis and decreasing the stromal barrier. The other segment, the RGD peptide-modified-liposome loading the chemotherapeutic drug gemcitabine, targeted and killed pancreatic tumor cells. This integrated nanomedicine, showing an increased drug perfusion without any overt side effects, may provide a potential strategy for improvement of the pancreatic cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9525 · Cited by 3,848
TGF-ß Signaling in Fibroblasts Modulates the Oncogenic Potential of Adjacent Epithelia
Bhowmick, N. A., Chytil, A., Plieth, D., Gorska, A. E., Dumont, N., Shappell, S., Washington, M. K., Neilson, E. G., & Moses, H. L. (2004) · Science · doi:10.1126/science.1090922 · Cited by 1,401
The role of stroma in pancreatic cancer: Diagnostic and therapeutic implications
Erkan, M., Hausmann, S., Michalski, C. W., Fingerle, A. A., Dobritz, M., Kleeff, J., & Friess, H. (2012) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2012.115 · Cited by 662
Cited by
Rational Design of Cancer Nanomedicine: Nanoproperty Integration and Synchronization
Sun, Q., Zhou, Z., Qiu, N., & Shen, Y. (2017) · Advanced Materials · doi:10.1002/adma.201606628 · Cited by 1,058
Current advance of nanotechnology in diagnosis and treatment for malignant tumors
Wang, B., Hu, S., Teng, Y., Chen, J., Wang, H., Xu, Y., Wang, K., Xu, J., Cheng, Y., & Gao, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01889-y · Cited by 558
Composition design and medical application of liposomes
Li, M., Du, C., Guo, N., Teng, Y., Meng, X., Sun, H., Li, S., Yu, P., & Galons, H. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.01.007 · Cited by 555
Self-citationEnzyme responsive drug delivery systems in cancer treatment
Shahriari, M., Zahiri, M., Abnous, K., Taghdisi, S. M., Ramezani, M., & Alibolandi, M. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.07.004 · Cited by 415
Tumor microenvironment-responsive intelligent nanoplatforms for cancer theranostics
Gong, F., Yang, N., Wang, X., Zhao, Q., Chen, Q., Liu, Z., & Cheng, L. (2020) · Nano Today · doi:10.1016/j.nantod.2020.100851 · Cited by 359
Han, X., Li, Y., Xu, Y., Zhao, X., Zhang, Y., Yang, X., Wang, Y., Zhao, R., Anderson, G. J., Zhao, Y., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05906-x · Cited by 339
Self-citationWei, H., Chen, J., Wang, S., Fu, F., Zhu, X., Wu, C., Liu, Z., Zhong, G., & Lin, J. (2019) · International Journal of Nanomedicine · doi:10.2147/ijn.s218988 · Cited by 317
“These nanocarriers have some advantages such as specific tumor targeting and accumulation, stabilized drug and easy release in tumor microenvironment.(3,4) Many materials have been used for preparing nanocarriers, such as nanogold particles,(5) carbon nanotubes,(6) micelles and liposomes,(7,8) polymeric nanoparticles(…”
MethodJi, T., Lang, J., Wang, J., Cai, R., Zhang, Y., Qi, F., Zhang, L., Zhao, X., Wu, W., Hao, J., et al. (2017) · ACS Nano · doi:10.1021/acsnano.7b01026 · Cited by 222
Self-citationSmart Nanotherapeutic Targeting of Tumor Vasculature
Li, Z., Di, C., Li, S., Yang, X., & Nie, G. (2019) · Accounts of Chemical Research · doi:10.1021/acs.accounts.9b00283 · Cited by 196
Self-citationPancreatic cancer: Stroma and its current and emerging targeted therapies
Kota, J., Hancock, J., Kwon, J., & Korc, M. (2017) · Cancer Letters · doi:10.1016/j.canlet.2016.12.035 · Cited by 173
Role of Cyclodextrins in Nanoparticle-Based Drug Delivery Systems
Shelley, H., & Babu, R. J. (2018) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2018.03.021 · Cited by 173
Li, S., Zhang, Y., Wang, J., Zhao, Y., Ji, T., Zhao, X., Ding, Y., Zhao, X., Zhao, R., Li, F., et al. (2017) · Nature Biomedical Engineering · doi:10.1038/s41551-017-0115-8 · Cited by 171
Self-citationWang, J., Zhu, M., & Nie, G. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113974 · Cited by 153
Self-citationDe Lellis, L., Veschi, S., Tinari, N., Mokini, Z., Carradori, S., Brocco, D., Florio, R., Grassadonia, A., & Cama, A. (2021) · Cancers · doi:10.3390/cancers13163946 · Cited by 40
“In vitro/ animal models A liposome-based nanomedicine integrating pirfenidone and gemcitabine induces downregulation of collagen I and TGF-β in PSCs; slowdown of tumor growth in mice co-implanted with PC cells and PSCs through decreased stromal fibrosis and increased drug perfusion [69,70]”
Background
Metadata
- Authors
- Ji, T., Li, S., Zhang, Y., Lang, J., Ding, Y., Zhao, X., Zhao, R., Li, Y., Shi, J., Hao, J., Zhao, Y., & Nie, G.
- Venue
- ACS Applied Materials & Interfaces
- Publisher
- American Chemical Society (ACS)
- Published
- 2016-01-26
- Volume
- 8
- Issue
- 5
- Pages
- 3438-3445
- ISSN
- 1944-8244 (ISSN-L)
- 1944-8252
- OpenAlex
- W2238838979
- Cited by
- 140
- References
- 3
- FWCI
- 6.64
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.